19 results match your criteria: "Centre Hospitalo-Universitaire (CHU) de Toulouse[Affiliation]"

Aggressive NK-cell leukaemia: Diverse morphology, distinct clinical features.

Br J Haematol

November 2024

Laboratoire d'Hématologie, Centre Hospitalo-Universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, UPS, Toulouse, France.

View Article and Find Full Text PDF

Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e.

View Article and Find Full Text PDF

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.

Clin Microbiol Infect

June 2024

Service de Maladies Infectieuses et Tropicales, Centre Hospitalo-universitaire (CHU) de Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM, Université Toulouse III, Toulouse, France. Electronic address:

Article Synopsis
  • Bispecific antibodies (BsAbs) are used to treat relapsed or refractory multiple myeloma, but frequent infections were noted during clinical trials, indicating a need for further real-world data on infection risks and outcomes.
  • A multicenter retrospective study involving 229 patients in France from December 2020 to February 2023 found a high incidence of infections, with 234 recorded cases, primarily affecting the respiratory system, and a hospitalization rate of 56%.
  • The study identified corticosteroids used for managing cytokine release syndrome as a risk factor for infections, while using GPRC5D-targeting BsAbs and antibacterial prophylaxis was associated with a reduced risk.
View Article and Find Full Text PDF

Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.

Cell Rep

August 2023

Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada; Department of Lab Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Ophthalmology and Vision Science, University of Toronto, Toronto, ON, Canada. Electronic address:

The neddylation inhibitor MLN4924/Pevonedistat is in clinical trials for multiple cancers. Efficacy is generally attributed to cullin RING ligase (CRL) inhibition, but the contribution of non-CRL targets is unknown. Here, CRISPR screens map MLN4924-monotherapy sensitivity in retinoblastoma to a classic DNA damage-induced p53/E2F3/BAX-dependent death effector network, which synergizes with Nutlin3a or Navitoclax.

View Article and Find Full Text PDF

Background: Postoperative frequently occurs in the elderly after hip fracture surgery and is associated with poor outcomes. Our aim was to identify a correlation between the atropinic burden (AB) due to drugs with clinical antimuscarinic effect and the occurrence of postoperative .

Methods: We carried out a prospective, monocentric, observational study including 67 patients over 65 years of age who underwent hip fracture surgery.

View Article and Find Full Text PDF

According to expert guidelines, lymph node surgical excision is the standard of care for lymphoma diagnosis. However, core needle biopsy (CNB) has become widely accepted as part of the lymphoma diagnostic workup over the past decades. The aim of this study was to present the largest multicenter inventory of lymph nodes sampled either by CNB or surgical excision in patients with suspected lymphoma and to compare their diagnostic performance in routine pathologic practice.

View Article and Find Full Text PDF
Article Synopsis
  • High-dose melphalan (HDM) combined with bortezomib (Bor-HDM) was tested in a phase 3 trial for patients with multiple myeloma to see if it was more effective than HDM alone.* -
  • The trial included 300 patients, and results showed no significant differences in complete response rates or minimum residual disease rates between the two treatment groups.* -
  • Although progression-free survival was slightly better in the Bor-HDM group (34.0 months) compared to HDM (29.6 months), the overall survival rates and serious adverse events were similar, indicating Bor-HDM did not provide a clear advantage.*
View Article and Find Full Text PDF

Soluble CD163 and incident cardiovascular events in patients with systemic lupus erythematosus: An observational cohort study.

J Intern Med

September 2022

Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris (APHP), Institut national de la santé et de la recherche médicale (INSERM) U1149, Université de Paris, Paris, France.

View Article and Find Full Text PDF

Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study).

Rheumatology (Oxford)

November 2022

Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM) U1149, Université de Paris, Paris.

Objective: The detection of somatic mutations among the genes of myeloid cells in asymptomatic patients-defining clonal haematopoiesis of indeterminate potential (CHIP)-is associated with a predisposition to cardiovascular events (CVEs) in the general population. We aimed to determine whether CHIP was associated with CVEs in SLE patients.

Methods: The study is an ancillary study of the randomized, double-blind, placebo-controlled, multicentre PLUS trial conducted from June 2007 through August 2010 at 37 centres in France, involving 573 SLE patients.

View Article and Find Full Text PDF

Autophagy a Close Relative of AML Biology.

Biology (Basel)

June 2021

Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France.

Article Synopsis
  • Autophagy, or "self-eating", is a crucial cellular process that helps regulate metabolism and is linked to cancer development and treatment resistance, but its role in tumors is still debated.
  • In acute myeloid leukemia (AML), autophagy promotes cell growth and survival of leukemic stem cells while supporting energy production through processes like lipophagy.
  • This review discusses how autophagy contributes to the transformation of normal stem cells into leukemia and its dual effect on chemotherapeutic efficacy, acting as either protective or harmful depending on the treatment used.
View Article and Find Full Text PDF

Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal. The phase 3 ICARIA-MM trial (NCT02990338) showed that isatuximab plus pomalidomide-dexamethasone prolongs median progression-free survival (mPFS) in patients with relapsed/refractory MM (RRMM). This subgroup analysis of ICARIA-MM compared the benefit of isatuximab in high-risk [defined by the presence of del(17p), t(4;14) or t(14;16)] versus standard-risk patients.

View Article and Find Full Text PDF

Highly sensitive serum cardiac troponin T and cardiovascular events in patients with systemic lupus erythematosus (TROPOPLUS study).

Rheumatology (Oxford)

March 2021

Département de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris (APHP), Institut national de la santé et de la recherche médicale (INSERM) U1149, Université de Paris, France.

Objective: Identification of biological markers able to better stratify cardiovascular risks in SLE patients is needed. We aimed to determine whether serum cardiac troponin T (cTnT) levels measured with a highly sensitive assay [high sensitivity cTnT (HS-cTnT)] may predict cardiovascular events (CVEs) in SLE.

Method: All SLE patients included between 2007 and 2010 in the randomized, double-blind, placebo-controlled, multicentre PLUS trial were screened.

View Article and Find Full Text PDF

Lu-DOTATATE is an effective treatment for inoperable metastatic well-differentiated pancreatic neuroendocrine tumors. There are no guidelines for patients with terminal renal failure. We present the case of a 74-year-old woman who received different lines of treatment: analogs of somatostatin, chemotherapy, a first series of peptide receptor radionuclide therapy (PRRT), and finally chemoembolization.

View Article and Find Full Text PDF

Diagnosis of an intestinal mucormycosis 'fungus ball' located with PET/CT with [F] FDG-PET/CT.

Eur J Hybrid Imaging

December 2019

Department of Nuclear Medicine, Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), 1, av Irène Joliot-Curie, 31059, Toulouse, France.

Mucormycosis is a life-threatening infection with most commonly rhino-orbital-cerebral and pulmonary syndromes that mostly occurs in immunocompromised patients. FDG-PET/CT emerged as a sensitive non-invasive tool to identify systemic mucormycosis. We present a 59-year-old woman for whom a PET/CT with F-FDG was performed in search of a primary location of mucormycosis with non-contributive conventional workup.

View Article and Find Full Text PDF

Aims: Potentially inappropriate drug prescribing (PIDP) is frequent in nursing home (NH) residents. We aimed to investigate whether a geriatric intervention on quality of care reduced PIDP.

Methods: We performed an ancillary study within a multicentric individually-tailored controlled trial (IQUARE trial).

View Article and Find Full Text PDF